Literature DB >> 11369635

Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system.

I D Lewis1, G Almeida-Porada, J Du, I R Lemischka, K A Moore, E D Zanjani, C M Verfaillie.   

Abstract

This report describes stroma-based and stroma-free cultures that maintain long-term engrafting hematopoietic cells for at least 14 days ex vivo. Umbilical cord blood (UCB) CD34(+) cells were cultured in transwells above AFT024 feeders with fetal-liver-tyrosine-kinase (FL) + stem cell factor (SCF) + interleukin 7 (IL-7), or FL + thrombopoietin (Tpo). CD34(+) progeny were transplanted into nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice or preimmune fetal sheep. SCID repopulating cells (SRC) with multilineage differentiation potential were maintained in FL-SCF-IL-7 or FL-Tpo containing cultures for up to 28 days. Marrow from mice highly engrafted with uncultured or expanded cells induced multilineage human hematopoiesis in 50% of secondary but not tertiary recipients. Day 7 expanded cells engrafted primary, secondary, and tertiary fetal sheep. Day 14 expanded cells, although engrafting primary and to a lesser degree secondary fetal sheep, failed to engraft tertiary recipients. SRC that can be transferred to secondary recipients were maintained for at least 14 days in medium containing glycosaminoglycans and cytokines found in stromal supernatants. This is the first demonstration that ex vivo culture in stroma-noncontact and stroma-free cultures maintains "long-term" engrafting cells, defined by their capacity to engraft secondary or tertiary hosts. (Blood. 2001;97:3441-3449)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369635     DOI: 10.1182/blood.v97.11.3441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Forward RNAi screens in primary human hematopoietic stem/progenitor cells.

Authors:  Nicole Ali; Christine Karlsson; Marie Aspling; Guang Hu; Nir Hacohen; David T Scadden; Jonas Larsson
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

2.  What is the future for cord blood stem cells?

Authors:  E A de Wynter
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 3.  Concise review: ex vivo expansion of cord blood-derived hematopoietic stem and progenitor cells: basic principles, experimental approaches, and impact in regenerative medicine.

Authors:  Patricia Flores-Guzmán; Verónica Fernández-Sánchez; Hector Mayani
Journal:  Stem Cells Transl Med       Date:  2013-10-07       Impact factor: 6.940

Review 4.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

5.  Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program.

Authors:  Michael G Daniel; Carlos-Filipe Pereira; Jeffrey M Bernitz; Ihor R Lemischka; Kateri Moore
Journal:  J Vis Exp       Date:  2016-12-16       Impact factor: 1.355

Review 6.  Ex vivo expansion of umbilical cord blood: where are we?

Authors:  Omar S Aljitawi
Journal:  Int J Hematol       Date:  2012-03-23       Impact factor: 2.490

7.  Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Authors:  Peter Ebeling; P Bach; U Sorg; A Schneider; T Trarbach; D Dilloo; H Hanenberg; S Niesert; S Seeber; T Moritz; M Flasshove
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-20       Impact factor: 4.553

Review 8.  Concise review: umbilical cord blood transplantation: past, present, and future.

Authors:  Javier Munoz; Nina Shah; Katayoun Rezvani; Chitra Hosing; Catherine M Bollard; Betul Oran; Amanda Olson; Uday Popat; Jeffrey Molldrem; Ian K McNiece; Elizabeth J Shpall
Journal:  Stem Cells Transl Med       Date:  2014-11-05       Impact factor: 6.940

9.  Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency.

Authors:  Felicia D Goodrum; Craig T Jordan; Kevin High; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

10.  Human hematopoietic stem cells can survive in vitro for several months.

Authors:  Taro Ishigaki; Kazuhiro Sudo; Takashi Hiroyama; Kenichi Miharada; Haruhiko Ninomiya; Shigeru Chiba; Toshiro Nagasawa; Yukio Nakamura
Journal:  Adv Hematol       Date:  2008-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.